FibroBiologics (FBLG) had its "hold" rating reaffirmed by D. Boral Capital.
FibroBiologics Announces Reverse Stock Split to Regain Compliance with Nasdaq's Bid Price Requirement [Yahoo! Finance]
FibroBiologics Announces Reverse Stock Split to Regain Compliance with Nasdaq’s Bid Price Requirement
FibroBiologics (FBLG) had its "buy" rating reaffirmed by D. Boral Capital. They now have a $7.00 price target on the stock.
FibroBiologics Announces Advances in Burn Treatment Using Proprietary Fibroblast Spheroid Technology